09/23/21 5:46 PMNasdaq : FEMYconferencesFemasys Inc. to Present at The MedTech ConferenceFemasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced that Kathy Lee-Sepsick,RHEA-AIneutral
09/20/21 4:05 PMNasdaq : FEMYFemasys Inc. To Join the Russell Microcap® IndexFemasys Inc. (NASDAQ: FEMY) (“Femasys” or the “Company”), a biomedical company developing a suite of product candidates to transform women’s healthcare with minimally invasive, non-surgical, in-office technologies, announced that the Company has beenRHEA-AIneutral
09/01/21 4:05 PMNasdaq : FEMYmanagementFemasys Inc. Announces the Appointment of Edward Evantash, M.D. as Chief Medical OfficerFemasys Inc. (NASDAQ: FEMY), a biomedical company developing a suite of product candidates to transform women’s healthcareRHEA-AIneutral
08/11/21 4:05 PMNasdaq : FEMYearningsFemasys Inc. Announces Financial Results for the Second Quarter of 2021Completed initial public offering (“IPO”) raising net proceeds of $31.6 million Appointed Anne Morrissey to the Board of Directors, an industry expert with decades of medical device experience Initiated 792-patient, pivotal LOCAL trial after receipt of investigational device exemption (IDE)RHEA-AIneutral
07/20/21 8:31 AMNasdaq : FEMYFemasys Inc. Announces First Patient Treated in Pivotal Trial for FemaSeedFemasys Inc. (NASDAQ: FEMY), a biomedical company focused on transforming women's healthcare, today announced the initiation andRHEA-AIneutral
06/21/21 8:49 AMNasdaq : FEMYChardan Acts as Lead Left Bookrunner in Femasys' $34.45 Million IPOChardan, a global investment bank, today announced that it acted as lead left bookrunner in the successful closing of the $34.45 million IPO of Femasys, Inc. (NASDAQ: FEMY) a biomedical company focused on transforming women's healthcare by developing novelRHEA-AIneutral
